礼来-JPM-20240109.pdf

《礼来-JPM-20240109.pdf》由会员分享，可在线阅读，更多相关《礼来-JPM-20240109.pdf（12页珍藏版）》请在三个皮匠报告上搜索。

1、1 2024 Eli Lilly and Company DAVE RICKSChair and CEO,Eli Lilly and CompanyJ.P.Morgan Healthcare ConferenceJanuary 9,20242 2024 Eli Lilly and Company Safe Harbor ProvisionThis presentation contains forward-looking statements that are based on managements current expectations,but actual results may di

2、ffer materially due to various factors.The companys results may be affected by factors including,but not limited to,the risks and uncertainties in pharmaceutical research and development;competitive developments;regulatory actions;litigation and investigations;business development transactions;econo

3、mic conditions;and changes in laws and regulations,including health care reform.For additional information about the factors that affect the companys business,please see the companys latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission.Certain financia

4、l information in this presentation is presented on a non-GAAP basis.Investors should refer to the reconciliations included in this presentation and should consider the companys non-GAAP measures in addition to,not as a substitute for or superior to,measures prepared in accordance with GAAP.The compa

5、ny undertakes no duty to update forward-looking statements except as required by applicable law3 2024 Eli Lilly and Company NOT FOR PROMOTIONAL USELong-term performance underpinned by innovation focus,while obesity TAM*was the dominant narrative in 2023An eventful and productive 6 yearsLLY+653%DRG+6

6、3%DRG(ex-LLY&NVO)+21%1/9/201812/29/2023*TAM=Total Addressable Market4 2024 Eli Lilly and Company NOT FOR PROMOTIONAL USEAccelerating R&D timelinesSubstantial investment in each therapeutic area and in genetic medicines,with accelerated R&D timelinesFocus and speed have helped drive R&D productivityC